Corporate Profile

We are an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, we seek to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. Our OMNI® Surgical System is a safe, minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the leading cause of irreversible blindness. Our TearCare® System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids. TearCare is in development for the treatment of the signs and symptoms of evaporative dry eye, the primary form of dry eye disease which is the number one reason for a patient visit to an eyecare provider.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

16 Sep '21
Sight Sciences Seeks Injunction Related to Hydrus® Microstent’s Infringement MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc.
24 Aug '21
Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burden MENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc .

Recent Events

Featured Reports